You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: January 5, 2025

Details for Patent: 8,026,281


✉ Email this page to a colleague

« Back to Dashboard


Which drugs does patent 8,026,281 protect, and when does it expire?

Patent 8,026,281 protects ANTARA (MICRONIZED) and is included in one NDA.

Summary for Patent: 8,026,281
Title:Treating metabolic syndrome with fenofibrate
Abstract: A method of treating metabolic syndrome in a human diagnosed with metabolic syndrome by administering a therapeutically effective amount of fenofibrate over a treatment period. The results can include identifying a human as not having clinical metabolic syndrome after treatment, as compared to having metabolic syndrome before treatment.
Inventor(s): Doyle, Jr.; Ralph T. (Milford, NJ), Kling; Douglas F. (Parisippany, NJ), Rongen; Roelof M. L. (Caliton, NJ), Rotenberg; Keith S. (Danville, NJ)
Assignee: Lupin Atlantis Holdings, S.A. (Schaffhausen, CH)
Application Number:11/111,971
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent 8,026,281
Patent Claim Types:
see list of patent claims
Use; Delivery; Formulation; Composition; Dosage form;
Patent landscape, scope, and claims:

Understanding the Scope and Claims of United States Patent 8,026,281: A Comprehensive Analysis

Introduction

Patent 8,026,281, like any other patent, is a complex document that outlines the invention, its claims, and the scope of protection it offers. To fully understand this patent, it is crucial to delve into its various components, the patent landscape, and the tools available for analysis.

Patent Search and Retrieval

To begin analyzing Patent 8,026,281, one must first retrieve the patent document. The USPTO provides several tools for this purpose, including the Patent Public Search tool, which has replaced older search tools like PubEast and PubWest. This modern interface offers enhanced access to prior art and is a powerful resource for patent searching[1].

Patent Claims

The claims section of a patent is critical as it defines the scope of the invention and what is protected by the patent. For Patent 8,026,281, the claims must be carefully examined to understand what is being patented.

Claim Construction

Claim construction is a vital aspect of patent law. It involves interpreting the meaning of the terms used in the claims. A recent Federal Circuit decision, CoolIT Sys., Inc. v. Vidal, highlights the importance of clear and unambiguous claim terms to avoid unexpected claim constructions during litigation[2].

Consistency in Claim Terms

Patent drafters should ensure that terms are used consistently throughout the entire application. Any minor variations can impact claim constructions and lead to ambiguity. This consistency is essential for maintaining the integrity of the patent claims[2].

Patent Scope and Eligibility

The scope of a patent is determined by its claims, but it must also pass the test of patent eligibility under 35 U.S.C. § 101. The USPTO's two-pronged framework for subject matter eligibility is particularly relevant here.

Prong One and Prong Two of Step 2A

Under the two-pronged framework, Prong One determines if the claim recites an abstract idea, and if so, Prong Two evaluates whether the claim elements integrate the abstract idea into a practical application. For AI inventions, demonstrating a specific, concrete technological advancement or solution to a technical problem is crucial for overcoming section 101 rejections[4].

Analyzing the Patent Claims Research Dataset

The USPTO's Patent Claims Research Dataset provides detailed information on claims from US patents and applications. This dataset can be used to analyze the scope and trends of patent claims, including those of Patent 8,026,281. The dataset includes claim-level statistics and document-level statistics, offering insights into the patent's scope and how it fits within the broader patent landscape[3].

Global and Local Resources

Global Dossier

The Global Dossier service allows users to access the file histories of related applications from participating IP Offices. This can be useful for understanding the global patent family of Patent 8,026,281 and how it is treated in different jurisdictions[1].

Patent and Trademark Resource Centers (PTRCs)

Local PTRCs provide additional resources and training in patent search techniques, which can be invaluable for a detailed analysis of Patent 8,026,281. These centers offer access to local search resources and expert assistance[1].

Public Search Facilities

The USPTO Public Search Facility in Alexandria, VA, and other public search facilities offer access to patent and trademark information in various formats. Trained staff are available to assist in navigating these resources, which can be particularly useful for in-depth analysis[1].

Common Citation Document (CCD)

The CCD application consolidates prior art cited by participating IP Offices for the family members of a patent application. This tool helps in visualizing the search results for the same invention produced by several offices, providing a comprehensive view of the prior art relevant to Patent 8,026,281[1].

Sequence Listings and Other Mega Items

For patents involving sequences or mega items, the Publication Site for Issued and Published Sequences (PSIPS) website is a valuable resource. It provides access to sequence listings, tables, and other mega items for granted US patents or published US patent applications[1].

Patent Assignment Search

Understanding the ownership and assignment history of a patent is crucial. The Patent Assignment Search website allows users to search for patent assignments and changes in ownership, providing insights into the current and past ownership of Patent 8,026,281[1].

Legal and Policy Considerations

Small Claims Patent Court

While not directly related to the analysis of a specific patent, the concept of a small claims patent court, as studied by the Administrative Conference of the United States (ACUS), highlights the broader legal and policy landscape in which patents operate. This study addresses the feasibility and structure of such a court, which could impact how patent disputes are handled in the future[5].

Key Takeaways

  • Clear Claim Terms: Ensure that claim terms are clearly defined and consistently used to avoid ambiguity and unexpected claim constructions.
  • Patent Eligibility: Demonstrate practical applicability and technological advancements to overcome section 101 rejections, especially for AI inventions.
  • Global and Local Resources: Utilize tools like the Global Dossier, PTRCs, and public search facilities to gain a comprehensive understanding of the patent.
  • Prior Art and Citation Data: Use tools like the CCD to consolidate and analyze prior art citations.
  • Sequence Listings and Mega Items: Access sequence listings and mega items through the PSIPS website if relevant to the patent.
  • Ownership and Assignment: Search for patent assignments to understand the current and past ownership of the patent.

FAQs

Q: How can I retrieve and analyze Patent 8,026,281?

A: You can retrieve the patent using the USPTO's Patent Public Search tool and analyze it by carefully examining the claims, description, and drawings. Additional resources like the Global Dossier and PTRCs can provide further insights.

Q: What is the importance of clear claim terms in a patent?

A: Clear claim terms are crucial to avoid ambiguity and unexpected claim constructions during litigation. Consistent use of terms throughout the application is essential.

Q: How do I determine if a patent is eligible under 35 U.S.C. § 101?

A: Use the USPTO's two-pronged framework to evaluate if the claim recites an abstract idea and if it integrates the abstract idea into a practical application.

Q: What resources are available for analyzing prior art and citation data?

A: The Common Citation Document (CCD) application consolidates prior art citations from participating IP Offices, providing a comprehensive view of the prior art.

Q: How can I find information on patent assignments and changes in ownership?

A: Use the Patent Assignment Search website to search for patent assignments and changes in ownership.

Sources

  1. USPTO - Search for patents: https://www.uspto.gov/patents/search
  2. Crowell - Do Your Patents Claim Engagement of Components as Intended?: https://www.crowell.com/en/insights/client-alerts/patent-counsel-do-your-patents-claim-engagement-of-components-as-intended
  3. USPTO - Patent Claims Research Dataset: https://www.uspto.gov/ip-policy/economic-research/research-datasets/patent-claims-research-dataset
  4. Baker Botts - The Importance of Prong Two of Step 2A for AI Inventions: https://www.bakerbotts.com/thought-leadership/publications/2024/september/the-importance-of-prong-two-of-step-2a-for-ai-inventions
  5. ACUS - U.S. Patent Small Claims Court: https://www.acus.gov/research-projects/us-patent-small-claims-court

More… ↓

⤷  Subscribe


Drugs Protected by US Patent 8,026,281

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Lupin ANTARA (MICRONIZED) fenofibrate CAPSULE;ORAL 021695-004 Oct 18, 2013 DISCN Yes No ⤷  Subscribe ⤷  Subscribe TREATING SEVERE HYPERTRIGLYCERIDEMIA ⤷  Subscribe
Lupin ANTARA (MICRONIZED) fenofibrate CAPSULE;ORAL 021695-004 Oct 18, 2013 DISCN Yes No ⤷  Subscribe ⤷  Subscribe TREATING PRIMARY HYPERCHOLESTEROLEMIA AND MIXED DYSLIPIDEMIA ⤷  Subscribe
Lupin ANTARA (MICRONIZED) fenofibrate CAPSULE;ORAL 021695-005 Oct 18, 2013 DISCN Yes No ⤷  Subscribe ⤷  Subscribe TREATING PRIMARY HYPERCHOLESTEROLEMIA AND MIXED DYSLIPIDEMIA ⤷  Subscribe
Lupin ANTARA (MICRONIZED) fenofibrate CAPSULE;ORAL 021695-005 Oct 18, 2013 DISCN Yes No ⤷  Subscribe ⤷  Subscribe TREATING SEVERE HYPERTRIGLYCERIDEMIA ⤷  Subscribe
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.